“`html
Maze Therapeutics Inc (Symbol: MAZE) shares recently traded at $41.49, surpassing the average analyst 12-month target price of $40.14. There are seven analysts covering the stock, with target prices ranging from $34.00 to $50.00, resulting in a standard deviation of $6.644.
Currently, the analyst ratings for MAZE include 8 strong buy ratings, 1 hold rating, and no sell ratings. The average rating stands at 1.22, indicating a generally positive outlook, where 1 is a strong buy and 5 is a strong sell.
“`
